Alpha-1 adrenergic neurons are sympathetic nervous system neurons that utilize norepinephrine as their primary neurotransmitter. These neurons express alpha-1 adrenergic receptors (ADRA1A, ADRA1B, ADRA1D) and play critical roles in regulating cardiovascular function, pupil dilation, bladder control, and visceral organ function. In the context of neurodegeneration, these neurons provide crucial noradrenergic innervation to various brain regions and peripheral organs, and their dysfunction contributes to several neurodegenerative disease processes.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000109 | adrenergic neuron |
The alpha-1 adrenergic receptor signaling cascade involves multiple downstream pathways[1]:
| Component | Role | Relevance |
|---|---|---|
| ADRA1A/B/D | Gq-coupled receptors | Primary drug targets |
| PLCB1-4 | Phospholipase C isoforms | Signal transduction |
| PRKCA/B/G | Protein kinase C | Downstream signaling |
| RAF1/ARAF/BRAF | MAPK kinase kinases | Cell proliferation |
| AKT1/2/3 | Akt kinases | Cell survival |
Alpha-1 adrenergic neurons project from the locus coeruleus to widespread cortical and hippocampal targets[2]. In Alzheimer's disease:
The sympathetic nervous system is affected in Parkinson's disease[4]:
MSA involves profound autonomic failure linked to alpha-1 adrenergic neuron degeneration[5]:
Autonomic dysfunction in ALS includes alpha-1 adrenergic system alterations[6]:
| Gene | Protein | Function |
|---|---|---|
| TH | Tyrosine hydroxylase | Rate-limiting enzyme |
| DDC | Aromatic L-amino acid decarboxylase | Dopamine-to-norepinephrine |
| DBH | Dopamine beta-hydroxylase | Dopamine-to-norepinephrine |
| PNMT | Phenylethanolamine N-methyltransferase | Epinephrine synthesis |
| Gene | Protein | Function |
|---|---|---|
| ADRA1A | Alpha-1A adrenergic receptor | Gq-coupled, main subtype |
| ADRA1B | Alpha-1B adrenergic receptor | Gq-coupled |
| ADRA1D | Alpha-1D adrenergic receptor | Gq-coupled, vascular |
| Gene | Protein | Function |
|---|---|---|
| SLC6A2 | Norepinephrine transporter | Reuptake |
| SLC18A2 | VMAT2 | Vesicular storage |
| Drug Class | Examples | Mechanism |
|---|---|---|
| Alpha-1 Agonists | Midodrine, droxidopa | Increase blood pressure |
| Alpha-1 Antagonists | Prazosin, terazosin | Lower blood pressure |
Shen et al. Gq-coupled adrenergic receptor signaling (2021). Trends in Pharmacological Sciences. 2021. ↩︎
Weinshenker, Noradrenergic signaling and Alzheimer's disease (2018). Brain Research. 2018. ↩︎
Chalermpalanupap et al. Targeting adrenergic receptors in Alzheimer's disease (2023). Neurobiology of Disease. 2023. ↩︎
Jain et al. Cardiac sympathetic denervation in Parkinson's disease (2019). Movement Disorders. 2019. ↩︎
Kimmerly et al. Autonomic dysfunction in multiple system atrophy (2022). Clinical Autonomic Research. 2022. ↩︎
Picillo et al. Cardiovascular autonomic dysfunction in ALS (2021). Neurology. 2021. ↩︎